The treatment of chronic hepatitis C in HIV-infected patients: A meta-analysis

HIV Medicine

Volumn 8, Issue 5, 2007, Pages 312-321

  Kim, A I ^a   Dorn, A ^b   Bouajram, R ^a   Saab, Sammy ^b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis C; HIV; Interferon treatment

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ERYTHROPOIETIN; LACTIC ACID; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL LIPASE;

ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEMATOLOGIC DISEASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; MEDLINE; META ANALYSIS; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 34250206927     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00476.x     Document Type: Article

References (45)

1. Fleming P, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV prevalence in the United States. Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002: Alexandria, VA. Foundation for Retrovirology and Human Health, 2002.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with Human Immunodeficiency Virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34 (6): 831-837.
3. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
4. Soriano V, Sulkowski M, Bergin C et al. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-828.
5. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
6. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36: S201-S209.
7. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
8. De Luca A, Bugarini R, Lepri AC et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Italian Cohort Naive Antiretrovirals Study Group. Arch Intern Med 2002; 162: 2125-2132.
9. Roca B, Suarez I, Gonzalez J et al. Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J Infect 2003; 47: 117-124.
10. Liang TJ, Rehermann B, Seeff L, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
11. Seeff L, Hoofnagle JH. The National Institutes of Health Consensus Development Conference Management of Hepatitis C. Appendix. Clin Liver Dis 2003, 2002; 7: 261-287.
12. Farci P, Alter HJ, Wong D et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98-104.
13. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
14. Detels R, Munoz A, McFarlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497-1503.
15. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
16. Murphy EL, Collier AC, Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
17. Cacoub P, Geffray L, Rosenthal E et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-1214.
18. Lewden C, Bonnet F, Bevilacqua S et al. Causes of death in HIV-infected French drug users, 1995-2000. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine; Groupe 'Mortalite 2000'. Ann Medical Interne 2002; 153: 2S4-10.
19. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
20. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467-1471.
21. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-247.
22. Puoti M, Spinetti A, Ghezzi A et al. Mortality for liver disease in patients with HIV infection: A cohort study. J Acquir Immune Defic Syndr 2000; 24: 211-217.
23. Di Martino V, Rufat P, Boyer N et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001; 34: 1193-1199.
24. Benhamou Y, Bochet M, Di M et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
25. Fuster D, Planas R, Muga R et al. Advanced liver fibrosis in HIV/ HCV-coinfected patients on antiretroviral therapy. IDS Res Hum Retroviruses2004; 20: 1293-1297.
26. Mohsen AH, Easterbrook PJ, Taylor C et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035-1040.
27. Ibrahim AB, Shpaner A, Nieto J, Saab S. Liver fibrosis is accelerated in HIV/HCV coinfection: A matched analysis. SA Gastroenterol Rev 2004; 2: 14-17.
28. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
29. Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Grupo Andaluz para el Estudio de las Enfermedades Infecciosas; Grupo Andaluz para el Estudio del Higado. Hepatology 2005; 41: 779-789.
30. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: A cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-2354.
31. Kim AI, Saab S. Treatment of hepatitis C. Am J Med 2005; 118: 808-815.
32. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. PEGASYS International Study Group. Ann Intern Med 2004; 140: 346-355.
33. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
34. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-965.
35. Division of AIDS table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1992.
36. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clin Trials 1996; 17: 1-12.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-188.
38. Egger M, Smith GD, Phillips AN. Meta-analysis. Principles and procedures. Br Med J 1997; 315: 1533-1537.
39. Cargnel A, Angeli E, Mainini A et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Italian Co-infection Study Group. Antivir Ther 2005; 10: 309-317.
40. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. ANRS HCO2 RIBAVIC Study Team. JAMA 2004; 292: 2839-2848.
41. Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. AIDS Clinical Trials Group A5071 Study Team. N Engl J Med 2004; 351: 451-459.
42. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-F36.
43. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. APRICOT Study Group. N Engl J Med 2004; 351: 438-450.
44. Crespo M, Esteban JI, Sauleda S et al. Early prediction of sustained virological response in patients with chronic hepatitis C and HIV infection treated with IFN+RBV. Hepatology 2004; 40: 350A.
45. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.